A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Study sponsor: PTC Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-07Actual
Enrollment · participants6Actual
Source updated2024-04-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.